Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

News SummaryMost relevantAll newsSector news 

Watson Says Received Favorable Ruling Over Generic Sanctura XR

share with twitter share with LinkedIn share with facebook
share via e-mail
04/04/2012 | 12:19am CEST

Watson Pharmaceuticals Inc. (>> Watson Pharmaceuticals, Inc.) said it received a favorable court ruling over a patent dispute with Allergan Inc. (AGN) and its business partners regarding Watson's plans for a generic version of an overactive bladder medication.

Allergan and its partners in 2009 sued Watson and its business partners, alleging infringement of patents related to Allergan's Sanctura XR drug.

Watson said Tuesday a U.S. District Court in Delaware found several Sanctura XR patents invalid, benefiting Watson and allowing it to potentially move forward with its abbreviated new drug application for generic version of the drug, which is pending with the Food and Drug Administration.

An Allergan representative wasn't immediately available for comment.

Watson has seen strong sales of its generics as health-care companies and consumers try to reduce spending on health-related products and services. Watson is trying to expand its brand-name drug business, though it recently hit a regulatory setback with a proposed new drug to prevent premature births.

The company benefited from its introduction of authorized generic versions of Johnson & Johnson's (JNJ) Concerta treatment for attention-deficit/hyperactivity disorder in May, as well as Pfizer's (PFE) Lipitor cholesterol-lowering drug in November.

Watson in February said its fourth-quarter profit surged as the introduction of generic Lipitor and other products boosted sales.

Watson's shares closed Tuesday at $66.96 and were down 6 cents after hours. Allergan's shares closed at $95.27 and were off 10 cents after hours.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; ben.rubin@dowjones.com

Stocks mentioned in the article : Watson Pharmaceuticals, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ACTAVIS INC
10/27DJPAUL BISARO : Allergan CEO Brent Saunders Succeeds Paul Bisaro as Chairman
10/14 U.S. targets corporate tax-reduction strategy with new regulation
10/05 Teva to sell Allergan's generics business in UK, Ireland for $769 million
10/05DJTEVA PHARMACEUTICAL INDUSTRIES : Sells Actavis Generics European Assets to Accor..
10/05DJTEVA PHARMACEUTICAL INDUSTRIES : Sells Actavis Generics European Assets to Accor..
10/05 AstraZeneca licenses respiratory drug to Insmed
10/03DJASTRAZENECA : Signs Deal with Allergan for Up To $1.52 Billion
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/14DJAllergan to Buy Vitae Pharmaceuticals for $639 Million
More news
Sector news : Pharmaceuticals - NEC
10/27DJPFIZER : Files 8K - Changes Executive Management
10/27DJApple Unveils Macs With Touch-Screen Keyboard
10/27 ASTRAZENECA : pauses two cancer drug trials' enrolment due to bleeding
10/27DJBRISTOL MYERS SQUIBB : Makes Moves to Reassure Investors
10/27DJBRISTOL MYERS SQUIBB : Makes Moves to Reassure Investors
More sector news : Pharmaceuticals - NEC
Financials ($)
Sales 2016 14 739 M
EBIT 2016 7 562 M
Net income 2016 -
Debt 2016 12 924 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 145,57
EV / Sales 2016 6,84x
EV / Sales 2017 6,08x
Capitalization 87 897 M
More Financials
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 298 $
Spread / Average Target 34%
Consensus details
EPS Revisions
More Estimates Revisions
Brenton L. Saunders President, Chief Executive Officer & Director
Paul M. Bisaro Executive Chairman
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON11.53%313 422
ROCHE HOLDING LTD.-17.44%196 913
PFIZER INC.0.37%196 527
NOVARTIS AG-16.42%188 199
MERCK & CO., INC.15.24%168 318
More Results